| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
|
N Engl J Med
|
2004
|
12.20
|
|
2
|
Follicular lymphoma international prognostic index.
|
Blood
|
2004
|
7.20
|
|
3
|
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.
|
Cancer Cell
|
2003
|
6.11
|
|
4
|
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.
|
J Exp Med
|
2003
|
6.06
|
|
5
|
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.
|
N Engl J Med
|
2013
|
4.49
|
|
6
|
Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
|
Cancer
|
2005
|
2.91
|
|
7
|
Imputation methods to improve inference in SNP association studies.
|
Genet Epidemiol
|
2006
|
2.41
|
|
8
|
New treatment options have changed the survival of patients with follicular lymphoma.
|
J Clin Oncol
|
2005
|
2.40
|
|
9
|
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.
|
Blood
|
2004
|
2.13
|
|
10
|
Risk prediction using genome-wide association studies.
|
Genet Epidemiol
|
2010
|
2.03
|
|
11
|
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
|
J Clin Oncol
|
2008
|
1.56
|
|
12
|
Interim futility analysis with intermediate endpoints.
|
Clin Trials
|
2008
|
1.23
|
|
13
|
Semiparametric estimation exploiting covariate independence in two-phase randomized trials.
|
Biometrics
|
2008
|
1.21
|
|
14
|
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
|
J Clin Oncol
|
2012
|
1.17
|
|
15
|
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
|
Cancer
|
2012
|
1.16
|
|
16
|
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
|
Blood
|
2003
|
1.14
|
|
17
|
Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.
|
Proc Natl Acad Sci U S A
|
2012
|
1.13
|
|
18
|
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
|
Blood
|
2012
|
0.98
|
|
19
|
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.
|
Transplantation
|
2008
|
0.95
|
|
20
|
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.
|
Biol Blood Marrow Transplant
|
2003
|
0.94
|
|
21
|
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
|
J Clin Oncol
|
2010
|
0.91
|
|
22
|
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.
|
Invest New Drugs
|
2009
|
0.89
|
|
23
|
Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709.
|
Arch Otolaryngol Head Neck Surg
|
2007
|
0.87
|
|
24
|
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.
|
Clin Cancer Res
|
2013
|
0.86
|
|
25
|
Evaluating test statistics to select interesting genes in microarray experiments.
|
Hum Mol Genet
|
2002
|
0.86
|
|
26
|
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.
|
Clin Cancer Res
|
2013
|
0.86
|
|
27
|
MyoD is a tumor suppressor gene in medulloblastoma.
|
Cancer Res
|
2013
|
0.83
|
|
28
|
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.
|
Clin Trials
|
2013
|
0.82
|
|
29
|
Tearing as a test for mechanical characterization of thin adhesive films.
|
Nat Mater
|
2008
|
0.79
|
|
30
|
Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic.
|
J Pharm Pract
|
2013
|
0.78
|
|
31
|
Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.
|
J Clin Oncol
|
2003
|
0.76
|
|
32
|
The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies.
|
Urol Oncol
|
2004
|
0.75
|
|
33
|
The quality of post and cores made using a reduce-time casting technique.
|
Oper Dent
|
2009
|
0.75
|